Based in Irvine of California, Blockade is engaged in the development catheter based therapeutic devices for the treatment of cerebral aneurysms.
Blockade manufactures Barricade coil system, which is said to complement Balt’s product portfolio.
The company also produces a range of platinum coils, which features a short and flexible detachment zone for fast detachment times and minimal microcatheter kickback.
The acquisition will help Balt to focus on the development and commercialization of additional novel neurovascular devices for the treatment of aneurysms, stroke and other neurovascular conditions.
Balt International president Pascal Girin said: “This acquisition is a first strategic move towards transforming BALT into an integrated global neurovascular device company.
“Balt is recognized as a first mover in the market thanks to a world-class R&D team, which has proven its ability and rapidity to develop blockbuster products such as the LEO stent, the SILK flow diverter and the SONIC detachable tip micro catheter.”
Blockade Medical president and chief technology officer Dave Ferrera said: “Blockade Medical is excited to join the BALT team. We believe the neurovascular expertise at Blockade Medical will complement BALT’s efficient and innovative organization.
“Unlike most competitors, BALT masters the whole value chain from design, manufacturing to distribution.”
Balt is engaged in the development and manufacturing of interventional neuro radiology devices such as catheters, stents and coils.
Image: Balt International has acquired US firm Blockade Medical. Photo: courtesy of stockimages / FreeDigitalPhotos.net.
